NASDAQ:ASND Ascendis Pharma A/S Q2 2025 Earnings Report $183.37 -0.78 (-0.42%) As of 02:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Ascendis Pharma A/S EPS ResultsActual EPSN/AConsensus EPS -$1.42Beat/MissN/AOne Year Ago EPSN/AAscendis Pharma A/S Revenue ResultsActual RevenueN/AExpected Revenue$163.17 millionBeat/MissN/AYoY Revenue GrowthN/AAscendis Pharma A/S Announcement DetailsQuarterQ2 2025Date8/7/2025TimeAfter Market ClosesConference Call DateThursday, August 7, 2025Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Ascendis Pharma A/S Earnings HeadlinesAscendis Pharma A/S (NASDAQ:ASND) Receives $223.07 Consensus Target Price from BrokeragesAugust 2 at 3:51 AM | americanbankingnews.comAscendis Pharma’s Clinical Trial Update: Implications for InvestorsAugust 1, 2025 | tipranks.comYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…August 5 at 2:00 AM | Crypto 101 Media (Ad)Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025July 31, 2025 | globenewswire.comJPMorgan Chase & Co. Boosts Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $254.00July 31, 2025 | americanbankingnews.comFDA Approves SKYTROFA® (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone DeficiencyJuly 28, 2025 | globenewswire.comSee More Ascendis Pharma A/S Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ascendis Pharma A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ascendis Pharma A/S and other key companies, straight to your email. Email Address About Ascendis Pharma A/SAscendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.View Ascendis Pharma A/S ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Palantir Stock Soars After Blowout Earnings ReportAmazon's Earnings: What Comes Next and How to Play ItApple Stock: Big Earnings, Small Move—Time to Buy?Why Robinhood Just Added Upside Potential After a Q2 Earnings DipMicrosoft Blasts Past Earnings—What’s Next for MSFT?Visa Beats Q3 Earnings Expectations, So Why Did the Market Panic?Spotify's Q2 Earnings Plunge: An Opportunity or Ominous Signal? Upcoming Earnings Airbnb (8/6/2025)AppLovin (8/6/2025)DoorDash (8/6/2025)Fortinet (8/6/2025)Brookfield Asset Management (8/6/2025)Cencora (8/6/2025)CRH (8/6/2025)Walt Disney (8/6/2025)Emerson Electric (8/6/2025)Energy Transfer (8/6/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
